US-based urological treatment technology developer SonoMotion received $10m of series B funding on Tuesday in a round co-led by medical device producer Advanced MedTech.
The deal was also co-led by life sciences-focused investment firm BioVentures Investors and Japan-focused medical device investment unit MedVentures Partners.
Founded in 2014, SonoMotion develops non-invasive devices to treat kidney stones, painful deposits of mineral and salts which can lead to infections and impaired urological function.
The company aims to launch an ultrasound-powered kidney stone repositioning treatment, dubbed Stone Clear, in 2020, and will use the series B capital for a study on its second product, Break Wave, intended to break apart problematic stones.
SonoMotion estimates more than three million US patients seek medical advice for kidney stones each year, with more than 700,000 procedures prescribed subsequently for large occlusions.
Existing treatments involve ultrasound shockwaves under general anaesthetic – a technique termed extracorporeal shock wave lithotripsy – or removing the stones by making an incision into the patient’s kidney via their back.
SonoMotion previously closed a $4.6m series A round in 2017 led by MedVenture Partners with participation from Bioventures Investors.